意大利重度特应性皮炎患者中「高剂量」与「中剂量」UVA1光疗的比较
该随机对照开放标签两臂试验连续纳入27例成人重度特应性皮炎(AD)患者,分别接受高剂量(130 J/cm²)或中剂量(60 J/cm²)UVA1光疗,每周5次至3周。所有患者SCORAD指数均下降;在深色皮肤类型及高黑色素指数患者中高剂量UVA1疗效显著优于中剂量(P<0.0001),而在II型皮肤组中两种方案无显著差异。
要点
- 高剂量UVA1(130 J/cm²)与中剂量(60 J/cm²)均每周5次治疗3周,所有患者SCORAD指数均下降。
- 深色皮肤类型且黑色素指数较高的患者中,高剂量UVA1疗效显著优于中剂量(P<0.0001)。
- II型皮肤患者中,高剂量与中剂量UVA1方案之间未观察到显著差异。
核心结论
- UVA1光疗应被视为重度泛发性AD患者的首选方法之一,且在深色皮肤类型的成人重度AD患者中高剂量UVA1光疗比中剂量更有效。
研究设计与样本
- 随机、对照、开放、两臂试验,连续纳入27例成人重度AD患者,13例接受高剂量(130 J/cm²)UVA1,14例接受中剂量(60 J/cm²)UVA1,每周5次至3周。
主要发现
- 所有患者皮肤状态改善,所有组SCORAD指数均下降。
- 深色皮肤类型且黑色素指数较高的患者中,高剂量UVA1疗效显著优于中剂量(P<0.0001)。
- II型皮肤组中,高剂量与中剂量方案之间未观察到显著差异。
关键数值与推荐
- 高剂量UVA1方案为130 J/cm²,中剂量UVA1方案为60 J/cm²,均每周5次至3周。
- 深色皮肤类型且黑色素指数较高患者中,高剂量UVA1疗效显著优于中剂量(P<0.0001)。
- II型皮肤组中高剂量与中剂量方案之间无显著差异。
临床怎么用
- 原文结论认为UVA1光疗应被视为重度泛发性AD患者的首选方法之一。
- 原文结论认为在深色皮肤类型的成人重度AD患者中,高剂量UVA1光疗比中剂量更有效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current evidences attest UVA1 phototherapy as effective in the treatment of severe atopic dermatitis (AD). Furthermore, in this indication, 'medium dose' is as effective as 'high dose' regimen. To date, a randomized comparison study evaluating the effectiveness as well as safety of different UVA1 protocols in different skin types in the treatment of adult patients with severe AD is still lacking. OBJECTIVE: The aim of the present study was to compare the safety and the efficacy of medium and high dose UVA1 either in fair or in dark skin types. METHODS: Twenty-seven adult patients with severe AD were consecutively included in a randomized, controlled, open, two arms trial Severity of AD was determined by means of SCORAD index and clinical improvement was also monitored. A total of 13 out of 27 patients were treated with high dose (130 J/cm2 ) UVA1 protocol while 14 out of 27 patients received medium dose (60 J/cm2 ) UVA1 protocol. Phototherapy was performed five times weekly up to 3 weeks. Before and after UVA1 treatment each patient was evaluated for skin pigmentation through Melanin Index (MI) quantitative evaluation. RESULTS: Skin status improved in all patients resulting in a reduction of SCORAD index in all groups. Our results demonstrated that among patients with darker skin types and higher MI, high dose UVA1 was significantly more effective than medium dose (P < 0.0001) while within the groups with skin type II, no significant differences between high and medium dose protocols were observed. CONCLUSION: Our study, confirms previous observations that UVA1 phototherapy should be considered among the first approaches in the treatment of patients with severe generalized AD and also demonstrates that in darker skin types, high dose UVA1 phototherapy is more effective than medium dose in the treatment of adult patients with severe AD.
引用
- Pacifico A, Iacovelli P, Damiani G, et al. 'High dose' vs. 'medium dose' UVA1 phototherapy in italian patients with severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2018. PMID: 30468530. doi:10.1111/jdv.15362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。